855477-01-9 Usage
Uses
Used in Pharmaceutical Industry:
3-Bromo-8-fluoroquinoline is used as a key intermediate in the synthesis of new drugs for the treatment of various diseases. Its unique structure allows for the development of innovative therapeutic agents with potential applications in medicine.
Used in Agrochemical Development:
In the agrochemical sector, 3-bromo-8-fluoroquinoline is utilized as a precursor in the creation of novel compounds designed to protect crops and enhance agricultural productivity.
Used in Materials Science:
3-Bromo-8-fluoroquinoline also finds application in the synthesis of functionalized quinolines for use in materials science, contributing to the advancement of new materials with specific properties for various industrial applications.
Used in Chemical and Biological Research:
Furthermore, 3-bromo-8-fluoroquinoline is employed as a starting material in chemical and biological studies, enabling researchers to explore its properties and potential interactions with other compounds for a wide range of scientific inquiries.
Check Digit Verification of cas no
The CAS Registry Mumber 855477-01-9 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 8,5,5,4,7 and 7 respectively; the second part has 2 digits, 0 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 855477-01:
(8*8)+(7*5)+(6*5)+(5*4)+(4*7)+(3*7)+(2*0)+(1*1)=199
199 % 10 = 9
So 855477-01-9 is a valid CAS Registry Number.
855477-01-9Relevant academic research and scientific papers
NOVEL NICOTINAMIDE DERIVATIVES OR SALTS THEREOF
-
Paragraph 0845; 0846, (2018/09/08)
An object of the present invention is to provide to a compound and a pharmaceutical composition, which have excellent Syk-inhibitory activity. Th e present invention provides a nicotinamide derivative represented by the follo wing formula (I) (wherein R 1 represents a halogen atom; R 2 represents a C 1-12 alkyl group, a C 2-12 alkenyl group, a C 2-12 alkynyl group, a C 3-8 cycloalkyl g roup, an aryl group, an ar-C 1-6 alkyl group or a heterocyclic group, each opti onally having at least one substituent; R 3 represents an aryl group or a hetero cyclic group each optionally having at least one substituent; and R 4 and R 5 e ach independently represent a hydrogen atom; and R 2 and R 4 may form a cyc lic amino group optionally having at least one substituent together with the ni trogen atom to which they bind) or a salt thereof, and a pharmaceutical comp osition for use in the treatment of a Syk-related disease which comprises the nicotinamide derivative or a salt thereof.
